|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-25 promotes the progression of HCC through inducing alternative activation and CXCL10 secretion of macrophages in tumor microenvironment, and IL-25 secretion may partly result from hyperplastic epithelial tuft cells in colon, induced by gut microbiota dysbiosis.
|
31296243 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that tumor-infiltrating Tregs (Ti-Tregs) failed to up-regulate CD39 in mice lacking EBI3 subunit of IL-27 or IL-27Ra.
|
30718407 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In cancer, IL-27 restricts tumor growth by acting on tumor cells directly, while its role in the tumor microenvironment is still controversially discussed.
|
31637217 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
There is a need to better understand how cytokines like IL-27, IL-30, and IL-35 interact with one another, and how a developing tumor can exploit these interactions to enhance immune suppression.
|
31681561 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In a plasmacytoma mouse model, we found that IL-10 was required for AAV-IL-27-mediated tumor rejection.
|
29618655 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our novel findings indicate that IL-27 directly acts on hematopoietic stem cells and promotes their expansion and differentiation into myeloid progenitors to control infection and to eradicate tumors.
|
29721372 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Advanced disease was associated with elevated tumor levels of tumor necrosis factor-alpha, interleukin (IL)-4, IL-10, IL-17A, and IL-17F, and only stage IV showed elevated systemic levels of Th17-associated cytokines IL-17F, IL-23, and IL-25.
|
27993206 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Finally, IL-27 showed a striking capability of up-regulating the expression of PD-L2 and HLA-I on tumor endothelium, whereas it did not modify that of PD-L1 and HLA-II.Our results suggest that cytokine-activated endogenous or adoptively transferred NK cells might support conventional therapies improving the outcome of MM patients.
|
28456791 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we will summarize IL-27 biological activities and its functional overlaps with the IFNs and discuss its dual role in tumors in the light of potential applications to cancer immunotherapy.
|
28255204 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-27 is predominantly synthesized by mononuclear phagocytes and exerts immunoregulatory functional activities on lymphocytic and nonlymphocytic cells during infection, autoimmunity or neoplasms.
|
28835457 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Three protein peaks (m/z 12,138, m/z 13,462, and m/z 15,120) that were significantly upregulated in the tumor tissue were identified as macrophage migration inhibitory factor (MIF), chemokine (C-X-C motif) ligand 7 (CXCL7), and interleukin 25 (IL-25).
|
28188039 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of IL-25 resulted in decreased type 2 T cells and macrophages in the primary tumor microenvironments, both reported to enhance breast tumor invasion and subsequent metastasis to the lung.
|
27909985 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Induction of IL-25 secretion from tumour-associated fibroblasts suppresses mammary tumour metastasis.
|
27089063 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Preclinical studies have revealed that the immune-regulatory cytokine IL-27 may exert anti-tumor activities in a variety of tumor types without discernable toxicity.
|
24681516 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, IL-27 and poly(I:C) cooperatively augmented TRAIL expression and inhibited tumor growth.
|
24155891 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-27 is the most recently characterized member of the family of heterodimeric IL-12-related cytokines and has shown promise in halting tumor growth and mediating tumor regression in several cancer models, including prostate cancer.
|
24028178 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results suggest that transfection of the IL-27 gene into human pancreatic carcinoma cells could produce antitumor effects in vivo and induction of cell cycle arrest and apoptosis could be the mechanism of IL-27 action in tumor regression.
|
22293948 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Apoptotic activity of IL-25 was mediated by differential expression of its receptor, IL-25R, which was expressed in high amounts in tumors from patients with poor prognoses but was low in nonmalignant breast tissue.
|
21490275 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-27 is the most recently characterized member of the family of heterodimeric IL-12-related cytokines and has shown promise in halting tumor growth and mediating tumor regression in several cancer models.
|
21801027 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gene transfer of IL-27 to tumor cells has been proven to inhibit tumor growth in vivo by antiproliferation, antiangiogenesis, and stimulation of immunoprotection.
|
19841177 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Deficiency of either the IL-27 subunit EBV-induced gene 3 or the IL-27 receptor WSX1 in the host animals had no effect on tumor growth inhibition induced by WSX1 expression in tumor cells.
|
19549909 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IL-27 augmented the expression of IFN regulatory factor (IRF)-1 and IRF-8, which possess tumor suppressor activities, in B16F10 transfectants expressing wild-type WSX-1.
|
18453571 |
2008 |